Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Dow JonesNov 28 08:07 ET

Morgan Stanley Maintains Kanzhun(BZ.US) With Buy Rating, Cuts Target Price to $15

Moomoo NewsNov 27 13:31 ET · Ratings

kanzhun-W(02076.HK): According to the share purchase plan after the initial public offering, a total of 0.4 million Class A ordinary shares will be bought.

November 27th, kanzhun-W (02076.HK) announced that on November 26, 2024, funded by internal company resources, the trustee plans to purchase a total of 0.4 million shares of Class A common stock (in the form of 0.2 million American depositary shares) on the open market according to the terms and conditions of the plan, and hold the shares in trust for eligible participants (as defined in the plan).

Gelonghui FinanceNov 27 03:32 ET

Kanzhun Trustee Purchases Another 390,618 Shares Under Post-IPO Scheme, Shares Down 7%

MT NewswiresNov 25 02:41 ET

kanzhun-W (02076.HK): Plans to purchase a total of 0.3906 million Class A common shares following the initial public offering.

Gelonghui, on November 25th, announced that kanzhun-W (02076.HK) stated that on November 22, 2024, internal resources will be allocated by the company to purchase a total of 390,618 Class A common shares (equivalent to 195,309 American Depositary Shares) in the open market, and hold these shares in a reits for eligible participants (as defined in the plan), at an average cost of $6.39 per Class A common share (excluding all relevant expenses).

Gelonghui FinanceNov 24 23:02 ET

Top Gap Ups and Downs on Thursday: SNOW, ANET, PDD and More

Moomoo NewsNov 21 18:00 ET · Markets